<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table III</label>
 <caption>
  <p>Candidate Product Profile (CPP) for Tilorone as a Broad-Spectrum Antiviral Therapeutic</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>
     <bold>Product Description</bold>
    </th>
    <th colspan="2">Tilorone dihydrochloride for oral use in the form of a tablet.</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>
     <bold>Mechanism of Action (MOA)</bold>
    </td>
    <td colspan="2">Tilorone dihydrochloride is an inhibitor of viral replication in mammalian host cells through activation of innate immunity signaling pathways. One such pathway may be the RIG-I-signaling pathway responsible for the sensing of intracellular viral RNA and activation of a cellular antiviral response. A further role may be via its lysosomotropic activity which could impact viral entry.</td>
   </tr>
   <tr>
    <td>
     <bold>Antiviral Activity</bold>
    </td>
    <td colspan="2">
     <p>
      <bold>EBOV:</bold> viral replication EC
      <sub>50</sub> = 230 nM; 100% survival at 30 mg/kg once daily intraperitoneal (IP) dosing in a mouse Ebola infection model (
      <xref ref-type="bibr" rid="CR36">36</xref>)
     </p>
     <p>
      <bold>
       <italic>In vitro</italic>
      </bold>
      <bold>activities*:</bold> CHIK (EC
      <sub>50</sub> = 4.2 μM), MERS-CoV (EC
      <sub>50</sub> = 3.7 μM), VEEV (EC
      <sub>50</sub> = 18 μM), ZIKV (EC
      <sub>50</sub> = 5.2 μM).
     </p>
     <p>
      <bold>Literature activities:</bold> HBV and HCV, Herpes Simplex Virus, Influenza A and B virus, Mengo Virus, Semliki Forest Virus, Vesicular Stomatitus Virus, and West Nile Fever Virus (
      <xref ref-type="bibr" rid="CR8">8</xref>).
     </p>
     <p>
      <bold>*</bold>
      <italic>In vitro</italic> antiviral potencies can vary greatly depending on the host cell types and the innate immunity genes expressed in the cell line. For example, Vero 76 cells lack interferon (IFN) pathways and generally show lower activities for Tilorone.
     </p>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Pharmacology</bold>
    </td>
    <td colspan="2">
     <p>
      <bold>Human Pharmacology:</bold> After oral administration, it is rapidly absorbed from the digestive tract. Bioavailability is 60%. Binding to plasma proteins is ~80%. It is not subject to biotransformation. T
      <sub>1/2</sub> = 48 h, and is excreted unchanged in feces (70%) and urine (9%). It does not accumulate (
      <xref ref-type="bibr" rid="CR24">24</xref>) (
      <xref ref-type="bibr" rid="CR11">11</xref>).
     </p>
     <p>
      <bold>Mouse Pharmacokinetics:</bold> At 10 mg/kg IP dosing: t
      <sub>1/2</sub> = 19 h; T
      <sub>max</sub> = 0.25 h; C
      <sub>max</sub> = 113 ng/mL; AUC
      <sub>last</sub> = 806 h·ng/mL; Cl/F = 249,000 ml/h/kg; V/F = 8880 ml/kg. (
      <xref ref-type="bibr" rid="CR36">36</xref>)
     </p>
     <p>
      <bold>
       <italic>In Vitro</italic>
      </bold>
      <bold>Drug Properties:</bold> Solubility: 470 μM in PBS pH 7.4; Permeability: high (Papp = 20 × 10
      <sup>−6</sup> cm/s in CACO-2 assay); not a Pgp substrate; plasma protein binding: human = 52%, mouse = 61%; plasma stability (5 h): human = 95%, mouse = 95%; liver microsomal stability: mouse t
      <sub>1/2</sub> = 48 min. (
      <xref ref-type="bibr" rid="CR36">36</xref>)
     </p>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Indications and Usage</bold>
    </td>
    <td colspan="2">
     <p>• Treatment of EBOV</p>
     <p>• Post-exposure Prophylaxis of EBOV</p>
     <p>• Treatment of acute infections from ZIKV, CHIK, SARS-CoV, MERS-CoV, and/or influenza.</p>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Primary Efficacy Endpoints</bold>
    </td>
    <td>
     <bold>
      <italic>Target:</italic>
     </bold> 100% efficacy in EBOV animal studies with ≤10% survival among controls
    </td>
    <td>
     <bold>
      <italic>Minimal:</italic>
     </bold> 60% efficacy in EBOV animal studies with ≤10% survival among controls
    </td>
   </tr>
   <tr>
    <td>
     <bold>Secondary Efficacy Endpoints</bold>
    </td>
    <td>
     <p>
      <bold>
       <italic>Target:</italic>
      </bold> Broad species coverage
     </p>
     <p>(Zaire and Sudan EBOV and</p>
     <p>Marburg virus; Bundibugyo</p>
     <p>EBOV)</p>
    </td>
    <td>
     <bold>
      <italic>Minimal:</italic>
     </bold> Zaire and Sudan EBOV
    </td>
   </tr>
   <tr>
    <td>
     <bold>Expected Safety Outcomes</bold>
    </td>
    <td>
     <bold>
      <italic>Target:</italic>
     </bold> No serious adverse effects
    </td>
    <td>
     <bold>
      <italic>Minimal:</italic>
     </bold> Acceptable therapeutic index to support treatment for lifethreatening
    </td>
   </tr>
   <tr>
    <td>
     <p>
      <bold>Dosage and</bold>
     </p>
     <p>
      <bold>Administration</bold>
     </p>
    </td>
    <td>
     <bold>
      <italic>Target:</italic>
     </bold> Efficacious when administered post-symptomatically; once daily dosing for up to 7 days
    </td>
    <td>
     <bold>
      <italic>Minimal:</italic>
     </bold> Efficacious when administered post-exposure; twicedaily dosing for up to 7 days
    </td>
   </tr>
   <tr>
    <td>
     <bold>Produce Stability and Storage</bold>
    </td>
    <td>
     <p>
      <bold>
       <italic>Target:</italic>
      </bold> Shelf life of at least
     </p>
     <p>24 months without refrigeration</p>
    </td>
    <td>
     <bold>
      <italic>Minimal:</italic>
     </bold> Shelf life of at least 12 months without refrigeration
    </td>
   </tr>
   <tr>
    <td>
     <bold>Patient Populations</bold>
    </td>
    <td>
     <bold>
      <italic>Target:</italic>
     </bold> All age-groups and populations
    </td>
    <td>
     <p>
      <bold>
       <italic>Minimal:</italic>
      </bold> All healthy adults,
     </p>
     <p>excluding pregnant and lactating women</p>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Contraindications</bold>
    </td>
    <td colspan="2">
     <italic>Possible contraindications from Russian labeling:</italic> Hypersensitivity, pregnancy, breastfeeding, children under 7 years.
    </td>
   </tr>
   <tr>
    <td>
     <bold>Drug Interactions</bold>
    </td>
    <td colspan="2">
     <p>Compatible with antibiotics and other drugs for the treatment of viral and bacterial diseases.</p>
     <p>
      <bold>CYP450 Inhibition Screening</bold>: IC
      <sub>50</sub> &gt; 50 μM for 1A2, 2C9,
     </p>
     <p>2C19, 2D6, 3A4 (
      <xref ref-type="bibr" rid="CR36">36</xref>)
     </p>
    </td>
   </tr>
   <tr>
    <td>
     <bold>How Supplied</bold>
    </td>
    <td colspan="2">Tablets supplied in a single dosage strength and packaged for maximal stability in high-humidity and warm temperature environments.</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
